| Methods |
Cluster‐randomisation by households, quasi‐randomisation by order of admission to hospital, open, no loss to f/u |
| Participants |
Household contacts, Nigeria |
| Interventions |
Rifampin: 0 to 2 years: 4 x 75 mg; 2 to 4 years 4 x 150 mg; 5 to 14 years 4 x 300 mg; 15+ years 4 x 600 mg versus sulphadimidine: 0 to 4 years 4 x 250 mg; 5 to 14 years 4 x 500 mg; 15+ years 4 x 1 G |
| Outcomes |
Morbidity, eradication, resistance developed
Follow‐up: 6 to 7 weeks |
| Notes |
Data presented for carriers. Main serogroup: A |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
High risk |
Quasi‐randomisation |
| Allocation concealment (selection bias) |
High risk |
Inadequate |
| Blinding of participants and personnel (performance bias)
All outcomes |
High risk |
Open |
| Blinding of outcome assessment (detection bias)
All outcomes |
High risk |
Open |
| Incomplete outcome data (attrition bias)
All outcomes |
Low risk |
No loss to f/u |
| Selective reporting (reporting bias) |
Low risk |
No evidence |
| Other bias |
Low risk |
No evidence |
